GlassScriptPhysician profile
Kevin Charles Westra
NPI 1518945070
$4,420.91
in general payments reported to CMS, 2019-2025
35 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $143 · 2021: $634 · 2022: $829 · 2023: $882 · 2024: $863 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,598 · Education: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.18 |
| Education | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,328.12 | 2019-2025 | Mavyret, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $608.41 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $502.40 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.24 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $264.94 | 2024 | Livdelzi, Epclusa |
| Genzyme Corporation | $194.29 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $154.59 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $151.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $84.11 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $70.59 | 2021-2023 | Dificid, Zinplava |
| Ferring Pharmaceuticals INC. | $68.94 | 2020-2024 | Rebyota |
| Celgene Corporation | $61.33 | 2021-2023 | |
| Qol Medical, LLC | $60.54 | 2019-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $59.11 | 2022-2025 | |
| Pfizer INC. | $57.55 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.75 | 2024-2025 | Omvoh |
| Amgen INC. | $41.25 | 2023-2025 | Amjevita, Uplizna |
| Ironwood Pharmaceuticals, INC | $40.02 | 2021-2022 | |
| Novo Nordisk INC | $35.11 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $29.52 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $26.09 | 2024-2025 | Voquezna |
| Organon LLC | $26.03 | 2024 | |
| Redhill Biopharma INC. | $24.49 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.12 | 2024 | |
| Daiichi Sankyo INC. | $20.83 | 2023 | Injectafer |
| Celltrion USA INC. | $19.74 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2022 | |
| Braintree Laboratories, INC. | $18.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.95 | 2023 | Cyltezo |
| Albireo Pharma, INC. | $17.48 | 2022 | |
| Boston Scientific Corporation | $15.72 | 2023 | Spyscope Ds |
| Micro-Tech Endoscopy USA, INC. | $15.54 | 2023 | Lesionhunter |
| Ardelyx, INC. | $15.15 | 2024 | Ibsrela |
| Vivus LLC | $14.86 | 2019 | |
| Aimmune Therapeutics, INC. | $13.92 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Westra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.